vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $196.0M, roughly 1.7× Axsome Therapeutics, Inc.). Axsome Therapeutics, Inc. runs the higher net margin — -14.6% vs -18.0%, a 3.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -4.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
AXSM vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $334.0M |
| Net Profit | $-28.6M | $-60.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | -18.0% |
| Revenue YoY | 65.0% | -76.3% |
| Net Profit YoY | 61.9% | -170.6% |
| EPS (diluted) | $-0.55 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $196.0M | $334.0M | ||
| Q3 25 | $171.0M | $382.0M | ||
| Q2 25 | $150.0M | $397.0M | ||
| Q1 25 | $121.5M | $316.0M | ||
| Q4 24 | $118.8M | $336.0M | ||
| Q3 24 | $104.8M | $396.0M | ||
| Q2 24 | $87.2M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $-28.6M | $-60.0M | ||
| Q3 25 | $-47.2M | $105.0M | ||
| Q2 25 | $-48.0M | $87.0M | ||
| Q1 25 | $-59.4M | $61.0M | ||
| Q4 24 | $-74.9M | $85.0M | ||
| Q3 24 | $-64.6M | $102.0M | ||
| Q2 24 | $-79.3M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | -11.4% | ||
| Q3 25 | -27.0% | 46.6% | ||
| Q2 25 | -24.5% | 37.8% | ||
| Q1 25 | -46.9% | 35.4% | ||
| Q4 24 | -61.1% | 38.4% | ||
| Q3 24 | -59.8% | 43.2% | ||
| Q2 24 | -89.5% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | -14.6% | -18.0% | ||
| Q3 25 | -27.6% | 27.5% | ||
| Q2 25 | -32.0% | 21.9% | ||
| Q1 25 | -48.9% | 19.3% | ||
| Q4 24 | -63.1% | 25.3% | ||
| Q3 24 | -61.7% | 25.8% | ||
| Q2 24 | -91.0% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $-0.55 | $-0.77 | ||
| Q3 25 | $-0.94 | $1.36 | ||
| Q2 25 | $-0.97 | $1.13 | ||
| Q1 25 | $-1.22 | $0.78 | ||
| Q4 24 | $-1.54 | $1.06 | ||
| Q3 24 | $-1.34 | $1.29 | ||
| Q2 24 | $-1.67 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $468.0M |
| Total Assets | $689.8M | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $322.9M | $64.0M | ||
| Q3 25 | $325.3M | $70.0M | ||
| Q2 25 | $303.0M | $50.0M | ||
| Q1 25 | $300.9M | $48.0M | ||
| Q4 24 | $315.4M | $103.0M | ||
| Q3 24 | $327.3M | $72.0M | ||
| Q2 24 | $315.7M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $88.3M | $468.0M | ||
| Q3 25 | $73.7M | $583.0M | ||
| Q2 25 | $73.1M | $570.0M | ||
| Q1 25 | $53.2M | $579.0M | ||
| Q4 24 | $57.0M | $650.0M | ||
| Q3 24 | $92.9M | $583.0M | ||
| Q2 24 | $102.9M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $689.8M | $4.2B | ||
| Q3 25 | $669.3M | $4.3B | ||
| Q2 25 | $639.8M | $4.3B | ||
| Q1 25 | $596.7M | $4.2B | ||
| Q4 24 | $568.5M | $4.2B | ||
| Q3 24 | $561.5M | $4.2B | ||
| Q2 24 | $548.2M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $367.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $168.0M |
| FCF MarginFCF / Revenue | -9.6% | 50.3% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $-18.7M | $152.0M | ||
| Q3 25 | $1.0M | $86.0M | ||
| Q2 25 | $-32.4M | $70.0M | ||
| Q1 25 | $-43.4M | $59.0M | ||
| Q4 24 | $-26.2M | $134.0M | ||
| Q3 24 | $-18.6M | $79.0M | ||
| Q2 24 | $-30.1M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $-18.7M | $136.0M | ||
| Q3 25 | $988.0K | $75.0M | ||
| Q2 25 | $-32.4M | $58.0M | ||
| Q1 25 | $-43.7M | $52.0M | ||
| Q4 24 | $-26.2M | $109.0M | ||
| Q3 24 | $-18.7M | $71.0M | ||
| Q2 24 | $-30.2M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | -9.6% | 40.7% | ||
| Q3 25 | 0.6% | 19.6% | ||
| Q2 25 | -21.6% | 14.6% | ||
| Q1 25 | -36.0% | 16.5% | ||
| Q4 24 | -22.1% | 32.4% | ||
| Q3 24 | -17.9% | 17.9% | ||
| Q2 24 | -34.6% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.3% | 2.2% | ||
| Q4 24 | 0.0% | 7.4% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.1% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
